

PATADAY (olopatadine hydrochloride 0.2%)

2mg/mL sterile ophthalmic solution

Basic Succinct Statement

CODE: BSS RD MAR 18; APPR 14 JAN 19

This material is only meant for Healthcare Professionals

PATADAY*

Important note: Before prescribing, consult full prescribing information.

Presentation: DROP-TAINER* dispenser. Each ml of solution contains 2 mg olopatadine and 0.1 mg benzalkonium chloride as a preservative.

Indications: Temporary prevention of itching of the eye due to allergic conjunctivitis.

Dosage and administration: The recommended dose is one drop in each affected eye once a day.

Contraindications: ♦Hypersensitivity to the active substance or to any of the excipients.

Warnings and Precautions: ♦**General:** PATADAY* contains benzalkonium chloride which may cause eye irritation and is known to discolour soft contact lenses. ♦Avoid contact with soft contact lenses. ♦Patients must be instructed to remove contact lenses prior to application of PATADAY* and wait at least 15 minutes before reinsertion. ♦**Ability to drive and use machines:** Olopatadine is a non-sedating anti-histamine. Temporary blurred vision after drop use, or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs after instillation, the patient must wait until the vision clears before driving or using machinery.

Adverse drug reactions: The following adverse reactions have been reported during clinical studies with olopatadine hydrochloride ophthalmic solution, 0.1% and 0.2% and are classified according to the subsequent convention: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) and very rare ($< 1/10,000$). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness. ♦**Uncommon:** headache, dysgeusia, punctate keratitis, keratitis, eye pain, dry eye, eyelid oedema, eye pruritus, eye discharge, ocular hyperaemia, eyelid margin crusting, ocular discomfort, nasal dryness, fatigue. ♦**Rare:** dizziness, photophobia, vision blurred, erythema of eyelid, dry mouth, dermatitis contact. ♦**Additional adverse reactions identified from post-marketing surveillance:** hypersensitivity, lacrimation increased, and nausea.